Mucopolysaccharidosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Mucopolysaccharidosis – Drugs In Development, 2024 report and make more profitable business decisions.
Mucopolysaccharidosis (MPS) refers to a group of inherited metabolic disorders causing the accumulation of complex sugars in cells, affecting various organs. Classified into different types (I-VII), symptoms vary widely but may include skeletal abnormalities, organ enlargement, developmental delays, and impaired vision or hearing. Diagnosis involves genetic testing and enzyme assays. Treatment focuses on managing symptoms and may involve enzyme replacement therapy, stem cell transplantation, or supportive care. While not curable, therapies aim to improve quality of life. Early detection, multidisciplinary care, and ongoing monitoring help alleviate symptoms and improve outcomes for individuals with mucopolysaccharidosis.
The Mucopolysaccharidosis drugs in development market research report provide comprehensive information on the therapeutics under development for Mucopolysaccharidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mucopolysaccharidosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Mucopolysaccharidosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 86 molecules, with 80 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Mucopolysaccharidosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Mucopolysaccharidosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Mucopolysaccharidosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allievex CorpAmicus Therapeutics Inc
AngioChem Inc
Apteeus SAS
ArmaGen Inc
Bioasis Technologies Inc
BioStrategies LC
Capsida Biotherapeutics Inc
Chengdu Genevector Biotechnology Co Ltd
Cinnagen Co
Denali Therapeutics Inc
Dorphan SA
Duke University
EdiGene Inc
Eloxx Pharmaceuticals Inc
Esteve Pharmaceuticals SA
Gain Therapeutics Inc
GC Biopharma Corp
Generium
Hanmi Pharmaceuticals Co Ltd
Immusoft Corp
JCR Pharmaceuticals Co Ltd
Jupiter Neurosciences Inc
Lacerta Therapeutics Inc
Lysogene SAS
M6P Therapeutics
Mina Therapeutics Ltd
Neurogt Inc
Orchard Therapeutics Plc
Ossianix Inc
Paradigm Biopharmaceuticals Ltd
Phoenix Nest Inc
Pronacera Therapeutics SL
RegenxBio Inc
ReqMed Co Ltd
Seelos Therapeutics
Inc.
Sigilon Therapeutics Inc
Simon Fraser University
Swedish Orphan Biovitrum AB
Tega Therapeutics Inc
The Hospital for Sick Children
Ultragenyx Pharmaceutical Inc
University of Alabama
University of Montreal
University of Pennsylvania
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Mucopolysaccharidosis reports